Find News

Filter articles

Applied Filters

Showing 1041 to 1050 of 1072 results

European Commission targets alleged ‘pay-for-delay’ with pharma fines


The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.

US Supreme Court backs ‘rule-of-reason’ for pay-for-delay


A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.

Teva and Sun stung by $2 billion settlement


Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.

IPAB sets aside Sutent patent rejection


India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.

Shire settles with Teva over ADHD drug


Drug-maker Teva must wait until 2015 before selling generic versions of Shire’s Intuniv product, according to a patent settlement between the companies.

Takeda sues generics over heartburn drug


Japanese pharma company Takeda has sued generic drug-makers Impax and Sandoz for allegedly infringing a patent directed to its anti-heartburn drug Dexilant.

Actavis to buy Warner Chilcott

Ireland, US22-05-2013

Actavis announced on May 20 it will acquire specialty pharmaceutical company Warner Chilcott plc in a deal worth an estimated $5 billion.

IP key to US biosimilars success – report


Strong IP knowledge is one of four key factors to succeeding in the burgeoning US biosimilars market, according to an industry report.

AstraZeneca loses Seroquel appeal


The UK Court of Appeal has upheld the High Court’s decision that AstraZeneca’s patent for a sustained release formulation of anti-psychotic drug quetiapine is invalid.

Acura sues Ranbaxy over abuse-resistant generic


Acura Pharmaceuticals has sued Ranbaxy Laboratories to keep it from releasing a generic version of its immediate release tablet formulation of painkiller Oxecta.

Showing 1041 to 1050 of 1072 results